Related Experiment Video
Updated: Jul 13, 2026
11:37
Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression
Juliane M Wiehe1, Peter Ponsaerts, Markus T Rojewski
1Department of Internal Medicine II, University of Ulm, Ulm, Germany.
Journal of Cellular and Molecular Medicine
|July 20, 2007
Summary
mRNA nucleofection offers a safer, more efficient method for gene transfer into human progenitor cells. This non-viral approach enhances transfection rates in hematopoietic progenitor cells (HPC) and mesenchymal stromal cells (MSC) without compromising cell viability or differentiation potential.
Area of Science:
- Cell Biology
- Gene Therapy
- Biotechnology
Background:
- Gene transfer into human CD34+ hematopoietic progenitor cells (HPC) and mesenchymal stromal cells (MSC) is crucial for tissue engineering and gene therapy.
- Viral gene transfer methods carry risks such as tumorigenesis and immune responses.
- Non-viral gene transfer is safer but often less efficient and can cause high cell toxicity.
Purpose of the Study:
- To evaluate the efficiency and safety of mRNA-based nucleofection for gene transfer into human CD34+ HPC and MSC.
- To compare mRNA nucleofection with traditional plasmid-based nucleofection.
- To assess the impact of this method on cell viability and differentiation capacity.
Main Methods:
- Human CD34+ HPC and MSC were transfected using in vitro-transcribed mRNA encoding Delta-truncated low affinity nerve growth factor receptor (DeltaLNGFR).
- Nucleofection was employed as the non-viral gene transfer technique.
- Transfection efficiency, cell viability, and protein expression (DeltaLNGFR) were assessed via flow cytometry over 10 days; differentiation assays were performed post-selection.
Main Results:
- mRNA nucleofection resulted in significantly higher transfection efficiencies in both CD34+ HPC and MSC compared to plasmid-based nucleofection.
- The method demonstrated high cell viability, with no reduction in the differentiation potential of MSC into chondrocytes, adipocytes, and osteoblasts.
- HPC differentiation into erythroid (BFU-E) and myeloid lineages (CFU-GEMM, CFU-GM) was also unaffected by the mRNA transfection process.
Conclusions:
- mRNA-based nucleofection is a highly efficient, non-toxic method for transient gene expression in human progenitor cells.
- This technique offers a powerful alternative to viral methods and plasmid-based non-viral approaches.
- It holds promise for transiently manipulating stem cell function, potentially bridging gene therapy and tissue engineering applications.
